

Supplementary Table 5. Effect of ticagrelor-aspirin versus clopidogrel-aspirin on efficacy and safety outcomes stratified by non-HDL-C levels among patients with baseline LDL-C ≥ 2.6 mmol/L

Outcome	Non-HDL-C <3.5 mmol/L				Non-HDL-C ≥ 3.5 mmol/L				P for interaction
	Ticagrelor-aspirin	Clopidogrel-aspirin	Adjusted HR (95% CI)*	P	Ticagrelor-aspirin	Clopidogrel-aspirin	Adjusted HR (95% CI)*	P	
Primary outcome									
Stroke	14 (3.4)	34 (8.5)	0.35 (0.18–0.67)	0.001	94 (6.9)	104 (7.8)	0.83 (0.62–1.11)	0.204	0.033
Secondary outcome									
Stroke within 30 days	14 (3.4)	28 (7.0)	0.44 (0.23–0.86)	0.016	79 (5.8)	90 (6.8)	0.80 (0.59–1.10)	0.169	0.167
Composite vascular events [†]	22 (5.3)	42 (10.5)	0.46 (0.27–0.77)	0.004	106 (7.8)	121 (9.1)	0.81 (0.62–1.06)	0.121	0.102
Ischemic stroke	14 (3.4)	33 (8.3)	0.36 (0.19–0.69)	0.002	93 (6.8)	102 (7.7)	0.84 (0.63–1.12)	0.228	0.036
Disabling stroke [‡]	6 (1.4)	12 (3.0)	0.38 (0.13–1.11)	0.078	52 (3.8)	41 (3.1)	1.16 (0.76–1.77)	0.491	0.045
Primary safety outcome									
Severe or moderate bleeding [§]	1 (0.2)	3 (0.8)	0.33 (0.03–3.59)	0.364	4 (0.3)	2 (0.2)	2.30 (0.42–12.63)	0.339	0.216
Intracranial hemorrhage	0 (0.0)	1 (0.3)	NA		2 (0.2)	2 (0.2)	1.14 (0.16–8.16)	0.896	NA
Secondary safety outcome									
Any bleeding	21 (5.0)	13 (3.3)	1.79 (0.87–3.66)	0.113	68 (5.0)	28 (2.1)	2.51 (1.60–3.93)	<0.001	0.643
Mortality	2 (0.5)	2 (0.5)	0.37 (0.03–4.45)	0.430	4 (0.3)	3 (0.2)	1.07 (0.24–4.89)	0.927	0.536

Values are presented as n (%) unless otherwise indicated.

HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HR, hazard ratio; CI, confidence interval; NA, not applicable; TIA, transient ischemic attack; LOF, loss-of-function.

*Adjusted for age, sex, body mass index, Han ethnicity, medical history (hypertension, diabetes mellitus, dyslipidemia, previous ischemic stroke, previous transient ischemic attack), *CYP2C19* LOF allele carriers, previous antiplatelet therapy, previous lipid-lowering therapy, and symptomatic intracranial-artery stenosis; [†]Composite vascular events include ischemic stroke, hemorrhagic stroke, TIA, myocardial infarction, vascular death; [‡]A stroke defined as disabling if the patient had a modified Rankin scale score of >1 (indicating death or any degree of disability); [§]Severe or moderate bleeding and mild bleeding were defined according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) criteria.